Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma

There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores.
Source: EurekaAlert, https://www.eurekalert.org